

# Alessandro Vitale

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4573279/publications.pdf>

Version: 2024-02-01

226  
papers

5,763  
citations

71097

41  
h-index

95259

68  
g-index

229  
all docs

229  
docs citations

229  
times ranked

6027  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective validation of the Barcelona Clinic Liver Cancer staging system. <i>Journal of Hepatology</i> , 2006, 44, 723-731.	3.7	378
2	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 150-159.	4.2	289
3	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
4	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	3.7	166
5	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , 2004, 40, 124-131.	3.7	161
6	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 654-662.	10.7	135
7	Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. <i>Cancer</i> , 2015, 121, 3998-4006.	4.1	131
8	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 412-423.	3.7	119
9	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	8.4	113
10	Intention-to-Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 972-981.	4.7	111
11	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , 2017, 49, 121-137.	0.9	111
12	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	7.3	107
13	Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. <i>Liver Transplantation</i> , 2009, 15, 1278-1287.	2.4	105
14	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010, 51, 165-173.	7.3	93
15	Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. <i>Hepatology</i> , 2017, 66, 1910-1919.	7.3	91
16	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. <i>Journal of Hepatology</i> , 2014, 60, 290-297.	3.7	89
17	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	4.7	86
18	A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 814-821.	2.4	81

#	ARTICLE	IF	CITATIONS
19	Harm and Benefits of Primary Liver Resection and Salvage Transplantation for Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2010, 10, 619-627.	4.7	73
20	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 905-914.	7.3	69
21	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant. <i>JAMA Surgery</i> , 2020, 155, e204095.	4.3	67
22	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Annals of Surgical Oncology</i> , 2010, 17, 2290-2302.	1.5	66
23	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.9	66
24	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. <i>Digestive and Liver Disease</i> , 2010, 42, 55-60.	0.9	59
25	Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. <i>Hepatology International</i> , 2013, 7, 1050-1057.	4.2	59
26	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.4	59
27	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 34-42.	1.6	58
28	SERPINB3 is associated with TGF- $\beta$ 1 and cytoplasmic $\beta$ -catenin expression in hepatocellular carcinomas with poor prognosis. <i>British Journal of Cancer</i> , 2014, 110, 2708-2715.	6.4	57
29	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.9	57
30	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	12.1	57
31	Use of N-acetylcysteine during liver procurement: A prospective randomized controlled study. <i>Liver Transplantation</i> , 2013, 19, 135-144.	2.4	54
32	Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid?. <i>European Journal of Surgical Oncology</i> , 2008, 34, 256-262.	1.0	51
33	Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1260-1263.	0.6	51
34	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial. <i>Liver Transplantation</i> , 2011, 17, 167-177.	2.4	51
35	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 125-133.	4.1	51
36	Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on the number of patients needed to transplant as measure of transplant benefit. <i>Journal of Hepatology</i> , 2014, 60, 1165-1171.	3.7	50

#	ARTICLE	IF	CITATIONS
37	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure? Transplantation, 2010, 89, 1425-1429.	1.0	48
38	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 685-691.	1.7	48
39	De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver Transplantation. Transplantation Proceedings, 2009, 41, 1303-1305.	0.6	46
40	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transplantation, 2017, 23, 1103-1112.	2.4	46
41	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers, 2019, 11, 1689.	3.7	44
42	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. Annals of Surgical Oncology, 2015, 22, 1901-1907.	1.5	43
43	The survival benefit of liver transplantation in hepatocellular carcinoma patients. Digestive and Liver Disease, 2010, 42, 642-649.	0.9	42
44	BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver International, 2015, 35, 223-231.	3.9	41
45	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. Digestive and Liver Disease, 2018, 50, 1105-1114.	0.9	41
46	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	3.9	41
47	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. Journal of Vascular and Interventional Radiology, 2017, 28, 1495-1502.	0.5	40
48	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
49	The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. World Journal of Surgery, 2015, 39, 1474-1484.	1.6	37
50	A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. Journal of Surgical Oncology, 2016, 113, 420-426.	1.7	37
51	Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. Hpb, 2014, 16, 979-986.	0.3	36
52	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World Journal of Gastroenterology, 2016, 22, 232.	3.3	35
53	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. Acta Dermato-Venereologica, 2012, 92, 411-415.	1.3	34
54	Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit. Hepatology, 2017, 65, 1741-1748.	7.3	34

#	ARTICLE	IF	CITATIONS
55	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2004, 347, 129-138.	1.1	32
56	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. <i>Hepatology</i> , 2020, 71, 569-582.	7.3	30
57	Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. <i>JAMA Surgery</i> , 2021, 156, e213112.	4.3	30
58	Liver Resection for Breast Cancer Liver Metastases. <i>Annals of Surgery</i> , 2017, 265, 792-799.	4.2	29
59	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 213-220.	1.7	28
60	Risk Factors in Liver Retransplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2011, 43, 1110-1113.	0.6	28
61	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , 2015, 21, 1241-1249.	2.4	28
62	Transplant benefit for patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 9183.	3.3	28
63	Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. <i>Transplantation Proceedings</i> , 2012, 44, 1989-1991.	0.6	27
64	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
65	Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial. <i>Liver Transplantation</i> , 2019, 25, 242-251.	2.4	27
66	Liver transplantation using suboptimal grafts: Impact of donor harvesting technique. <i>Liver Transplantation</i> , 2007, 13, 1444-1450.	2.4	26
67	Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases. <i>Transplantation Proceedings</i> , 2011, 43, 1091-1094.	0.6	26
68	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
69	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. <i>Cell Death and Disease</i> , 2019, 10, 703.	6.3	25
70	Liver Autotransplantation for the Treatment of Unresectable Hepatic Metastasis: An Uncommon Indication—A Case Report. <i>Transplantation Proceedings</i> , 2012, 44, 1930-1933.	0.6	24
71	Laparoscopic Ablation of Hepatocellular Carcinoma in Cirrhotic Patients Unsuitable for Liver Resection or Percutaneous Treatment: A Cohort Study. <i>PLoS ONE</i> , 2013, 8, e57249.	2.5	24
72	The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria—In Patients Waiting for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1023-1033.	2.4	24

#	ARTICLE	IF	CITATIONS
73	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. <i>Surgery</i> , 2015, 158, 339-348.	1.9	23
74	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
75	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	3.7	21
76	Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?. <i>Cancers</i> , 2021, 13, 2274.	3.7	21
77	Liver transplantation for the management of hepatoblastoma. <i>Transplantation Proceedings</i> , 2003, 35, 2983-2985.	0.6	20
78	Progression of Hepatocellular Carcinoma Before Liver Transplantation: Dropout or Liver Transplantation?. <i>Transplantation Proceedings</i> , 2009, 41, 1264-1267.	0.6	20
79	Global management of a common, underrated surgical task during the COVID-19 pandemic: Gallstone disease - An international survey. <i>Annals of Medicine and Surgery</i> , 2020, 57, 95-102.	1.1	20
80	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. <i>Cancers</i> , 2020, 12, 452.	3.7	20
81	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016, 168, 122-133.	5.0	19
82	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , 2019, 120, 956-965.	1.7	19
83	Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 6920.	3.3	19
84	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. <i>Transplantation Proceedings</i> , 2003, 35, 2991-2994.	0.6	18
85	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1194-1196.	0.6	18
86	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. <i>Digestive and Liver Disease</i> , 2014, 46, 340-347.	0.9	18
87	Management of hepatitis C infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 4447-4456.	3.3	18
88	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. <i>Transplantation</i> , 2013, 95, 1528-1534.	1.0	17
89	Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis. <i>World Journal of Surgery</i> , 2015, 39, 2500-2509.	1.6	17
90	Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study. <i>Liver Transplantation</i> , 2004, 10, 692-698.	2.4	15

#	ARTICLE	IF	CITATIONS
91	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an inâ€field multicenter cohort study. <i>Liver International</i> , 2017, 37, 1184-1192.	3.9	15
92	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. <i>Personalized Medicine</i> , 2020, 17, 83-87.	1.5	15
93	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	3.7	15
94	Early Surgery for the Treatment of Toxic Megacolon. <i>Digestion</i> , 2005, 72, 146-149.	2.3	14
95	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 974-976.	0.6	14
96	Alcohol Abuse and De Novo Tumors in Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1310-1312.	0.6	13
97	Risk Factors for Early Mortality in Liver Transplant Patients. <i>Transplantation Proceedings</i> , 2019, 51, 179-183.	0.6	13
98	A 2020 update on liver transplant for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 885-900.	3.0	13
99	Prospective Validation of a New Priority Allocation Model for Liver Transplant Candidates: An Interim Analysis. <i>Transplantation Proceedings</i> , 2009, 41, 1092-1095.	0.6	12
100	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , 2014, 20, 1021-1028.	2.4	12
101	Readmission After Liver Resection for Intrahepatic Cholangiocarcinoma: a Multi-Institutional Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1334-1341.	1.7	12
102	Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 603-610.	2.4	12
103	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2005, 17, 713-716.	1.6	11
104	Multimodal therapy before liver transplantation for hepatocellular carcinoma. <i>Hepatology Research</i> , 2005, 31, 112-115.	3.4	11
105	Hepatitis C Virusâ€Related Cirrhosis as a Significant Mortality Factor in Intention-to-Treat Analysis in Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1901-1903.	0.6	11
106	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1096-1098.	0.6	11
107	Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 75-75.	3.0	11
108	Combined Liver and Kidney Transplantation: Analysis of Padova Experience. <i>Transplantation Proceedings</i> , 2007, 39, 1933-1935.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2223-2225.	0.6	10
110	Intensive Care Unit Admission of Decompensated Cirrhotic Patients: Prognostic Scoring Systems. <i>Transplantation Proceedings</i> , 2011, 43, 1079-1084.	0.6	10
111	Can liver transplantation provide the statistical cure?. <i>Liver Transplantation</i> , 2014, 20, 210-217.	2.4	10
112	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	2.4	10
113	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
114	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	4.9	10
115	Serum alkaline phosphatase, a risk factor for non-alcoholic fatty liver, but only for women in their 30s and 40s: evidence from a large cohort study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-8.	3.0	9
116	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	3.7	9
117	Liver transplantation for rare liver diseases and rare indications for liver transplant. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 27-27.	3.0	9
118	Colon Rectal Liver Metastases: The Role of the Liver Transplantation in the Era of the Transplant Oncology and Precision Medicine. <i>Frontiers in Surgery</i> , 2021, 8, 693387.	1.4	9
119	Long-Term Results of Liver Transplantation for Hepatocellular Carcinoma: An Update of the University of Padova Experience. <i>Transplantation Proceedings</i> , 2007, 39, 1892-1894.	0.6	8
120	Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1668-1675.	1.7	8
121	The NAFL Risk Score: A simple scoring model to predict 4-y risk for non-alcoholic fatty liver. <i>Clinica Chimica Acta</i> , 2017, 468, 17-24.	1.1	8
122	Liver radiofrequency ablation as emergency treatment for a ruptured hepatocellular carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 54.	0.8	8
123	Changing indications for liver transplant: slow decline of hepatitis viruses in Italy. <i>Infectious Diseases</i> , 2020, 52, 557-562.	2.8	8
124	Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. <i>Cancers</i> , 2021, 13, 1416.	3.7	8
125	Prognostic Impact of Model for End-Stage Liver Disease Score in Patients Undergoing Liver Transplantation With Suboptimal Livers. <i>Transplantation Proceedings</i> , 2007, 39, 1907-1909.	0.6	7
126	Urgency, utility, and time horizon of transplant benefit. <i>Liver Transplantation</i> , 2015, 21, 565-566.	2.4	7



#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	1.6	7
128	Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. <i>Digestive and Liver Disease</i> , 2018, 50, 156-162.	0.9	7
129	Resection for hepatocellular cancer: overpassing old barriers. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 64-64.	3.0	7
130	Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy?. <i>Cancers</i> , 2021, 13, 2406.	3.7	7
131	Treatment allocation in patients with hepatocellular carcinoma: Need for a paradigm shift?. <i>Liver Cancer International</i> , 2022, 3, 34-36.	1.3	7
132	Extreme marginal donor: severe hypothermia as a rare preservation condition for explantable organs—a case report. <i>Transplantation Proceedings</i> , 2003, 35, 1282-1284.	0.6	6
133	Syngeneic Living-Donor Liver Transplantation for Hemangioendothelioma: A Clinical Model for Studying Liver Regeneration. <i>American Journal of Transplantation</i> , 2005, 5, 2309-2314.	4.7	6
134	Neoadjuvant Therapy Protocol and Liver Transplantation in Combination With Pancreatoduodenectomy for the Treatment of Hilar Cholangiocarcinoma Occurring in a Case of Primary Sclerosing Cholangitis: Case Report With a More Than 8-Year Disease-Free Survival. <i>Transplantation Proceedings</i> , 2011, 43, 1187-1189.	0.6	6
135	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. <i>Transplant International</i> , 2013, 26, 138-144.	1.6	6
136	Towards a personalized approach to hepatic resection in cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 859-861.	3.7	6
137	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	7.7	6
138	Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma. <i>Clinical and Experimental Medicine</i> , 2021, 21, 675-682.	3.6	6
139	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , 2021, 9, 890.	3.2	6
140	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	4.9	6
141	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	2.0	6
142	Pediatric Liver Transplantation: The University of Padua Experience. <i>Transplantation Proceedings</i> , 2007, 39, 1939-1941.	0.6	5
143	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. <i>Transplant International</i> , 2011, 24, e23-e27.	1.6	5
144	Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection. <i>Transplantation Proceedings</i> , 2014, 46, 2287-2289.	0.6	5

#	ARTICLE	IF	CITATIONS
145	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	2.4	5
146	Clinical results of active scanning proton therapy for primary liver tumors. <i>Tumori</i> , 2021, 107, 71-79.	1.1	5
147	Thoracoscopic Ablation of Critically Located Liver Tumors: A Safety and Efficacy Cohort Study. <i>Frontiers in Surgery</i> , 2021, 8, 626297.	1.4	5
148	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 822507.	2.8	5
149	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation. <i>Frontiers in Oncology</i> , 2022, 12, 877107.	2.8	5
150	Liver Resection Associated With Mini Porto-Caval Shunt as Salvage Treatment in Patients With Progression of Hepatocellular Carcinoma Before Liver Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2010, 42, 1378-1380.	0.6	4
151	Video-laparoscopic MW ablation in a European high volume center: Safety and efficacy of 891 procedures. <i>Digestive and Liver Disease</i> , 2018, 50, 54-55.	0.9	4
152	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
153	Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies. <i>PLoS ONE</i> , 2011, 6, e23093.	2.5	4
154	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , 2020, 14, 855-867.	1.4	4
155	Multimodal approach and its impact on survival for patients with hepatocellular carcinoma. <i>Anticancer Research</i> , 2003, 23, 4047-53.	1.1	4
156	Impact of Positive Radial Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1680.	3.7	4
157	Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2012, 44, 361-362.	0.9	3
158	Liver Transplantation in Children With Congenital Cardiac Defects: A Case Report and a Short Literature Review. <i>Transplantation Proceedings</i> , 2013, 45, 2769-2773.	0.6	3
159	Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details. <i>Gastroenterology</i> , 2016, 150, 534-535.	1.3	3
160	Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resources' Allocation. <i>Transplantation Direct</i> , 2021, 7, e669.	1.6	3
161	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2004, 17, 713-716.	1.6	2
162	Alcohol- and Substance-Dependent Subjects: The Correlated Factors in Qualifying for Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1861-1863.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	1.8	2
164	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. <i>Journal of Hepatology</i> , 2013, 58, S48.	3.7	2
165	Prognostic Prediction and Identification of Candidates for Salvage Liver Transplantation Among Patients With Early Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2014, 20, 1150-1151.	2.4	2
166	P915 PREDICTION OF RECURRENCE AFTER LIVER TRANSPLANTATION FOR HCC: VALIDATION OF THE AFP MODEL IN AN ITALIAN COHORT. <i>Journal of Hepatology</i> , 2014, 60, S380.	3.7	2
167	Which Is the True Role of Bridging Therapies for HCC Patients Waiting for Liver Transplantation?. <i>Annals of Surgery</i> , 2018, 268, e56-e57.	4.2	2
168	Transplantation for hepatocellular cancer: pushing to the limits?. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 61-61.	3.0	2
169	BCLC staging system and liver transplantation: From a stage to a therapeutic hierarchy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 4-5.	1.3	2
170	Analysis of clinical course of portal vein thrombosis in cirrhosis with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2021, 53, S43.	0.9	2
171	NAFLD: a multi-faceted morbid spectrum with uncertain diagnosis and complicated management. <i>Minerva Surgery</i> , 2021, 76, 450-466.	0.6	2
172	Need for independence of treatment allocation from prognostic evaluation for hepatocellular carcinoma. <i>Liver Cancer International</i> , 0, , .	1.3	2
173	Reply: The easiest way to improve the outcome of suboptimal liver grafts. <i>Liver Transplantation</i> , 2008, 14, 906-907.	2.4	1
174	Benefit and harm of deceased- or living-donor liver transplantation for hepatocellular carcinoma. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 88-92.	0.2	1
175	Potential net health benefit of pre-transplant Sofosbuvir to prevent recurrence of HCV infection after liver transplantation: A multicenter, cohort model study. <i>Digestive and Liver Disease</i> , 2014, 46, e132-e133.	0.9	1
176	The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE). <i>Digestive and Liver Disease</i> , 2018, 50, 44.	0.9	1
177	Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma (HCC) undergoing trans-arterial chemoembolization (TACE). <i>Digestive and Liver Disease</i> , 2019, 51, e6.	0.9	1
178	Recent trends and intention-to-treat survival of liver transplantation for nonalcoholic steatohepatitis: an Italian liver transplant registry study. <i>Digestive and Liver Disease</i> , 2020, 52, e16-e17.	0.9	1
179	Liver Resection for Patients with Intermediate Stage Hepatocellular Carcinoma: Beyond Rigid Staging Systems Towards a More Personalized Therapeutic Approach. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1078-1079.	1.7	1
180	AF.79 EPIDEMIOLOGICAL TRENDS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH METABOLIC-DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) IN ITALY. <i>Digestive and Liver Disease</i> , 2021, 53, S173.	0.9	1

#	ARTICLE	IF	CITATIONS
181	Electronic Outpatient Referral System for Liver Transplant Improves Appropriateness and Allows First Visit Triage. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1388-e1415.	4.4	1
182	Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14563-e14563.	1.6	1
183	Laparoscopic and percutaneous microwave ablation to treat liver metastasis from colon cancer. A tool for long-term iterative strategy: results from a high volume center. <i>Hpb</i> , 2021, 23, S803-S804.	0.3	1
184	Peer review report 1 on "Risk of renal cancer in liver transplant recipients: A systematic review and meta-analysis". <i>International Journal of Surgery</i> , 2016, 25, 2.	2.7	0
185	Liver Retransplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 736-739.	0.6	0
186	Reply. <i>Liver Transplantation</i> , 2017, 23, 1630-1631.	2.4	0
187	Liver transplant organ allocation; preliminary results using the ISO score system. <i>Digestive and Liver Disease</i> , 2018, 50, 54.	0.9	0
188	Personalized management of patients with very early hypovascular hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 415-416.	3.9	0
189	Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: A multicenter cohort study. <i>Digestive and Liver Disease</i> , 2018, 50, 9-10.	0.9	0
190	Microwave ablation and salvage transplantation for patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2018, 50, 44-45.	0.9	0
191	Monofocal hepatocellular carcinoma (HCC): Is diameter so important? Analysis on the Italian Liver Cancer (ITA.LI.CA) database between BCLC algorithm and Milan criteria. <i>Digestive and Liver Disease</i> , 2018, 50, 53.	0.9	0
192	Reply. <i>Hepatology</i> , 2018, 67, 1639-1640.	7.3	0
193	Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis c treatment with new direct-acting antivirals: a multicenter cohort study. <i>Hpb</i> , 2018, 20, S192-S193.	0.3	0
194	Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: a multicenter cohort study. <i>Journal of Hepatology</i> , 2018, 68, S15.	3.7	0
195	The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE). <i>Journal of Hepatology</i> , 2018, 68, S198.	3.7	0
196	Monofocal HCC: Milan Criteria or BCLC staging system? An analysis of the ITA.LI.CA. Database. <i>Journal of Hepatology</i> , 2018, 68, S444.	3.7	0
197	SAT-480-Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report. <i>Journal of Hepatology</i> , 2019, 70, e844.	3.7	0
198	PS-119-Time-varying mHAP III is the most accurate score in predicting survival in patients with hepatocellular carcinoma undergoing trans-arterial chemoembolization. <i>Journal of Hepatology</i> , 2019, 70, e75.	3.7	0

#	ARTICLE	IF	CITATIONS
199	The time-varying survival benefit of HCC treatment: a multicenter cohort study. <i>Digestive and Liver Disease</i> , 2019, 51, e8.	0.9	0
200	Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in BCLC B patients: a propensity score analysis. <i>Digestive and Liver Disease</i> , 2019, 51, e13.	0.9	0
201	An intention-to-treat competing-risk model for candidates with hepatocellular cancer waiting for liver transplantation. <i>Digestive and Liver Disease</i> , 2019, 51, e13.	0.9	0
202	Video-laparoscopic MW ablation in a European high volume center: safety and efficacy of 970 procedures. <i>Hpb</i> , 2019, 21, S943.	0.3	0
203	Laparoscopic Microwave Ablation and Portal Vein Occlusion for Staged Hepatectomy (LAPS). <i>Hpb</i> , 2019, 21, S905.	0.3	0
204	Laparoscopic liver resection versus transarterial chemoembolization for hepatocellular carcinoma in child B cirrhosis: a propensity score analysis. <i>Hpb</i> , 2019, 21, S1006-S1007.	0.3	0
205	From individual to population-based benefit of split liver transplantation. <i>Digestive and Liver Disease</i> , 2019, 51, 181-182.	0.9	0
206	Reply. <i>Hepatology</i> , 2019, 69, 465-466.	7.3	0
207	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Digestive and Liver Disease</i> , 2020, 52, e56.	0.9	0
208	OC.05.1 MICRORNA-21 AND MICRORNA-122: PROGNOSIS PREDICTION AND CORRELATION WITH HIF-1ALPHA IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION. <i>Digestive and Liver Disease</i> , 2020, 52, S17-S18.	0.9	0
209	OC.05.2 INCREASING EPIDEMIOLOGICAL TRENDS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN ITALY. <i>Digestive and Liver Disease</i> , 2020, 52, S18.	0.9	0
210	T06.01.4 IMPACT OF PRE-TRANSPLANT SARCOPENIA ON SHORT TO MEDIUM TERM OUTCOME IN LIVER TRANSPLANT RECIPIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA. <i>Digestive and Liver Disease</i> , 2020, 52, S159.	0.9	0
211	Epidemiological trends of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease in Italy. <i>Digestive and Liver Disease</i> , 2020, 52, e49.	0.9	0
212	The impact of sarcopenia on the outcome of patients with cirrhosis with and without hepatocellular carcinoma who undergo liver transplantation. <i>Hepatoma Research</i> , 0, 2021, .	1.5	0
213	Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or "waiting and see" strategy?. <i>Digestive and Liver Disease</i> , 2021, 53, S8.	0.9	0
214	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. <i>Digestive and Liver Disease</i> , 2021, 53, S37-S38.	0.9	0
215	COVID-19 and Solid Organ Transplantation (SOT) in Italy: A web-survey. <i>Digestive and Liver Disease</i> , 2021, 53, S45-S46.	0.9	0
216	Impact of hospital volume on hepatocellular carcinoma survival in Italy. <i>Digestive and Liver Disease</i> , 2021, 53, S9-S10.	0.9	0

#	ARTICLE	IF	CITATIONS
217	Liver Transplantation during the COVID-19 pandemic: A quantitative model balancing individual patient benefit against population healthcare needs. <i>Digestive and Liver Disease</i> , 2021, 53, S44.	0.9	0
218	A Novel Entity Among Vascular Liver Tumors: The First Reported Liver Transplantation. Is It Feasible?. <i>Transplantation Proceedings</i> , 2021, 53, 1690-1693.	0.6	0
219	OC.04.6 CIRCULATING PROSTAGLANDIN E2: A NOVEL POTENTIAL PROGNOSTIC BIOMARKER IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. <i>Digestive and Liver Disease</i> , 2021, 53, S108-S109.	0.9	0
220	OC.04.5 IMPACT OF HOSPITAL VOLUME ON HEPATOCELLULAR CARCINOMA SURVIVAL IN ITALY. <i>Digestive and Liver Disease</i> , 2021, 53, S108.	0.9	0
221	OC.04.10 PROGNOSTIC ROLE OF PLATELETS-TO-LYMPHOCYTES RATIO (PLR) AND NEUTROPHILS-TO-LYMPHOCYTES RATIO (NLR) IN HEPATOCELLULAR CARCINOMA PATIENTS. <i>Digestive and Liver Disease</i> , 2021, 53, S110-S111.	0.9	0
222	An Intention-to-Treat Competing-Risk Model for Candidates with Hepatocellular Cancer Awaiting Liver Transplantation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
223	New trends and perspectives in hepatobiliary surgery: preface. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 99-99.	3.0	0
224	A Pig Model of Hemivascular Liver Occlusion for The Study of Ischemia-Reperfusion Injury: Use of an Infrared System for Detecting Ischemic Areas. , 2019, 4, .		0
225	Role of laparoscopic and robotic liver resection compared to open surgery in elderly hepatocellular carcinoma patients: a systematic review and meta-analysis. <i>Hepatoma Research</i> , 0, 2020, .	1.5	0
226	OC.05.6 GENDER-RELATED DIFFERENCES IN SCCA-IGM LEVELS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH TRANSARTERIAL CHEMOEMBOLIZATION. <i>Digestive and Liver Disease</i> , 2020, 52, S20-S21.	0.9	0